Use of NK-1 receptor antagonists for treating major depressive disorders
US6613765B1 · kind B1 · utility
0Cited by
8References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1998 |
| Grant date | Sep 2, 2003 |
| Priority date | — |
| Expiry date | Jun 11, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for the treatment of major depressive disorders comprising oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.